Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant, Inc. Chief Executive Officer Eric Venker reported a compensation-related equity transaction involving capped value appreciation rights (CVARs) and a small tax sale of common stock. On July 1, 2026, 92,188 vested CVARs were settled into shares of common stock after the service, performance, knock-in and hurdle price conditions were met. The same day, a Form 4 entry shows 86,629 shares of common stock disposed to the issuer at $38.14 per share. On July 2, 2026, he sold 3,092 shares of common stock at $38.48 per share in an open-market transaction, which the footnotes state was a mandatory “sell to cover” for tax withholding tied to the CVAR vesting rather than a discretionary sale. After these transactions, Venker directly holds 254,280 shares of Immunovant common stock.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported open-market sales of a total of 17,714 shares of common stock. The shares were sold in two transactions at weighted average prices of $38.18 and $38.95 per share, within disclosed intraday price ranges.
After these sales, she directly holds 224,393 shares of Immunovant common stock, indicating she retains a substantial equity position despite the net reduction.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 40,000 shares of Common Stock in open-market transactions. The sales on June 26, 2026 were executed at weighted average prices of $38.18 and $38.94 per share, with individual trades occurring between $37.74 and $39.13 per share.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported same-day stock option exercises and open-market sales of common stock. He exercised options for 17,824 shares at an exercise price of $15.20 per share and sold 17,824 shares in open-market transactions.
The reported sales were split into 2,842 shares at a weighted average price of $38.96 and 14,982 shares at a weighted average price of $38.19, with actual trade prices ranging from $37.75 to $39.15 per share. Following these transactions, he directly holds 180,597 Immunovant common shares and 53,707 stock options, which expire on April 1, 2035 and vest over time from an April 1, 2025 grant.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at a price of $15.90 per share and then sold 10,000 shares in open-market transactions at a weighted average price of $38.46 per share. After these transactions, he directly holds 247,596 Common Shares. The filing notes that the sale was executed in multiple trades between $38.00 and $38.90 per share.
Immunovant, Inc. director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. He exercised 1,500 stock options at $8.43 per share and sold 1,500 common shares at an average price of $38.01 per share pursuant to a Rule 10b5-1 plan adopted on December 26, 2025.
Following these transactions, he holds 116,731 common shares directly, 20,000 common shares indirectly through a trust, and 68,181 stock options (right to buy) remaining.
Issuer submitted a Form 144 notice for potential sales of Common stock under Rule 144. The filing lists multiple blocks of Restricted Stock Vesting Under a Registered Plan with specific vesting dates and share amounts, and includes a figure 40,000 near the securities header.
The entries show vesting events dated 04/17/2024, 07/17/2024, 10/17/2024, 01/02/2026, 01/17/2026, 04/01/2026, and 04/17/2026 with listed share quantities such as 17,761, 5,290, and others. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services and references NASDAQ.
Issuer submitted a Form 144 reporting planned sale tied to an exercise of options under a registered plan. The filing lists 17,824 shares with an intended sale date of 06/26/2026 and cash as the payment method. The filing also discloses prior dispositions: 2,634 shares sold on 06/18/2026 for $93,217.26 and 5,165 shares sold on 04/08/2026 for $128,246.95.
IMVT submitted a Rule 144 notice listing proposed sales of common stock tied to restricted stock vesting. The filing lists 17,714 shares associated with three vesting events dated 02/18/2026, 04/01/2026, and 05/18/2026
The entry shows an amount of $678,552.48 alongside the share totals and indicates the submission date 06/26/2026. The filing identifies the securities as restricted stock vesting under a registered plan and names Morgan Stanley Smith Barney LLC as a broker.